June 6, 2016 / 9:12 PM / in a year

BRIEF-Aeterna zentaris to file a NDA for zoptrex in first half of 2017

June 6 (Reuters) - Aeterna Zentaris Inc

* Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting

* Phase III trial for endometrial cancer expected to be completed in Q3 2016

* To file a new drug application for zoptrex in first half of 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below